Newm-035 «1080p 2025»

: Success in Phase I will lead to trials for children aged 2–7 with congenital anodontia (being born without a full set of teeth). Future Outlook

If clinical trials continue to show success, researchers aim to make TRG-035 commercially available by . This would offer a biological alternative to traditional prosthetic solutions like dental implants, bridges, or dentures. Japan Begins Human Trials for Tooth Regrowth Drug TRG-035 NEWM-035

: Launched in September 2024 at Kyoto University Hospital. This phase involves 30 healthy adult males aged 30–64 who are missing at least one molar, primarily focusing on safety and dosage. : Success in Phase I will lead to

Below is an overview of the development and science behind . TRG-035: The World's First Tooth Regrowth Drug Japan Begins Human Trials for Tooth Regrowth Drug

The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi.